Skip to main content
Clinical Trials/NCT01469871
NCT01469871CompletedPhase 4

Reduction of Tape Blisters After Hip Surgery. A Prospective Evaluation of Three Types of Dressings.

Hopital de l'Enfant-Jesus2 sites in 1 country150 target enrollmentStarted: February 1, 2009Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
150
Locations
2
Primary Endpoint
The prevalence of tape blisters after hip fracture surgery

Study Overview

Brief Summary

The purpose of this study is to determine if one of the new types of dressings (MEPORE PRO and/or MEPILEX BORDER ) will reduce the blister rate compared to the currently used HYPAFIX.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
45 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or Female 45 years old or older
  • Hip surgery at Hopital de l'Enfant-Jesus between 02/2009 and 01/2010 (THR,rTHR, DHS, screw fixation, hemiarthroplasty, resurfacing)
  • Signed consent form

Exclusion Criteria

  • Allergy to dressing
  • Polytrauma / high energy trauma
  • Wound at the surgical site prior to surgery
  • Neurological deficit of operated side (hemiplegia, etc.)
  • Bilateral fracture

Outcomes

Primary Outcomes

The prevalence of tape blisters after hip fracture surgery

Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days

Secondary Outcomes

  • Length of hospital stay(Participants will be followed for the duration of hospital stay, an expected average of 8 days)
  • The correlation between risk factors and tape blisters(Participants will be followed for the duration of hospital stay, an expected average of 8 days)
  • The possible link between the presence of tape blisters and hospital morbidity.(Participants will be followed for the duration of hospital stay, an expected average of 8 days)
  • The costs related to a tape blister.(Participants will be followed for the duration of hospital stay, an expected average of 8 days)

Investigators

Sponsor
Hopital de l'Enfant-Jesus
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Pelet Stephane

Dr Stephane Pelet MD, PhD Orthopedic surgeon

Hopital de l'Enfant-Jesus

Study Sites (2)

Loading locations...

Similar Trials